The iLet Bionic Pancreas is an FDA-cleared automated insulin delivery (AID) system from Beta Bionics that simplifies type 1 diabetes care by eliminating carb counting, basal rates, and correction dose calculations. Clinicians enter only the user’s body weight at setup; the algorithm learns and adjusts insulin dosing around the clock using continuous glucose monitor (CGM) data. It is cleared for people age 6 and older with type 1 diabetes.
What Makes the iLet Different
Most insulin pumps, including Tandem Control-IQ and Omnipod 5, require the user or clinician to program basal rates, insulin-to-carb ratios, correction factors, and active insulin time. These settings affect nearly every dose and need ongoing fine-tuning. The iLet strips those settings away. Its adaptive machine-learning algorithm replaces them with real-time decisions based on CGM data, body weight, and a simple qualitative meal announcement.
For people with type 1 diabetes and their caregivers, that means less math, fewer settings to worry about at 3 AM, and a gentler learning curve for new pump users. It is a meaningful advance for anyone exploring modern diabetes treatment options.
How the iLet Algorithm Works
The iLet is initialized with only the user’s body weight. From that value, the algorithm calculates an initial insulin dose profile, then adapts continuously as it receives CGM data. It makes three types of dosing decisions:
- Basal-like micro-boluses: Delivered every 5 minutes based on glucose trend.
- Meal boluses: Triggered by a qualitative meal announcement from the user.
- Correction boluses: Automatically delivered when glucose trends above target.
There is no “set and forget” basal rate to update seasonally. There is no correction factor to recalibrate after illness. The iLet’s internal model adjusts on its own.
Qualitative Meal Announcements Replace Carb Counting
Meal announcements are the biggest user-facing change. Instead of measuring 48 grams of carbohydrate for a bagel and entering that value, users simply select:
- Breakfast, Lunch, or Dinner — to tell the pump a meal is coming.
- Usual-for-me (default), more than usual, or less than usual.
The algorithm calibrates what “usual” means for each user over the first few weeks. For kids who eat unpredictable amounts and adults who dislike label-reading, this is a major quality-of-life improvement.
Clinical Evidence: What the Trials Show
The landmark multicenter randomized trial published in the New England Journal of Medicine in 2022 compared the iLet Bionic Pancreas with standard care in 326 adults and children with type 1 diabetes over 13 weeks.
| Outcome | iLet Group | Standard Care |
|---|---|---|
| Mean A1C at 13 weeks | 7.3% | 7.7% |
| Time in range 70-180 mg/dL | 65% | 54% |
| Time below 54 mg/dL | 0.3% | 0.3% |
| Severe hypoglycemia events | Similar | Similar |
The iLet improved average A1C by roughly 0.4 percentage points and added about 2.5 hours per day of in-range glucose time without raising hypoglycemia risk. Benefits were consistent across age groups and baseline A1C. For context on how A1C maps to glucose averages, see our A1C levels guide.
Who Can Use the iLet
FDA clearance applies to people age 6 and older with type 1 diabetes. It is not cleared for type 2 diabetes, pregnancy, or children under 6 — although clinical trials in these populations are ongoing. The user must be willing to wear a compatible CGM (Dexcom G6, Dexcom G7, or FreeStyle Libre 3 Plus) essentially continuously.
People switching from multiple daily injections (MDI) can often skip the usual “find your basal rate” titration process and go directly to automated delivery. Those switching from another pump need to disable their previous settings and accept a brief adaptation window while the iLet learns.
Insulins Compatible With the iLet
The iLet is cleared for use with rapid-acting and ultra-rapid-acting analog insulins, including Humalog (lispro), Novolog (aspart), Fiasp, Lyumjev, Admelog, and Apidra. Reservoir changes every 2-3 days; the pump uses pre-filled Fiasp cartridges in some markets and standard cartridges filled by the user in others.
Wearing and Using the Pump
The iLet is a small, rectangular, tubed pump with a touchscreen and reservoir. Infusion sets use standard Luer-lock connectors and are available from multiple manufacturers, giving users flexibility on site and cannula type. Daily interactions include:
- Announcing meals (3 taps).
- Confirming CGM is connected.
- Checking battery and reservoir levels.
- Changing the infusion set every 2-3 days.
Cost and Insurance Coverage
The iLet is covered under most commercial insurance plans and Medicare Part B pump benefits, though formulary inclusion can lag FDA clearance. Out-of-pocket costs for the pump and supplies are similar to other AID systems — typically $5,000-$7,000 upfront for the pump (before insurance) and $300-$500 per month for infusion sets and reservoirs. Beta Bionics has a patient assistance program for eligible users.
Limitations and Safety Notes
The iLet is not a cure. Users still need to:
- Wear a CGM continuously for the algorithm to function.
- Keep fast-acting glucose and glucagon available for rare lows.
- Switch to backup MDI if the pump fails or needs repair.
- Carry out infusion set and reservoir changes on schedule.
Exercise, illness, and rapid carbohydrate absorption can still cause glucose excursions. The algorithm handles most situations autonomously but is not infallible. As with any pump, ketone testing is recommended when glucose exceeds 250 mg/dL to rule out infusion-site failure or impending diabetic ketoacidosis.
The Bottom Line
The iLet Bionic Pancreas represents one of the simplest automated insulin delivery systems available today. By removing carb counting, basal rates, and correction factors, it reduces the mental burden of type 1 diabetes without sacrificing time-in-range or safety. It is a strong fit for newly diagnosed users, pediatric patients, and anyone overwhelmed by traditional pump settings.
Switching pumps is a significant decision. Discuss options with your endocrinologist, confirm CGM compatibility and insurance coverage, and compare alternatives such as Tandem Control-IQ and Omnipod 5 before committing. For broader context on where insulin delivery fits within diabetes care, see our treatment hub.
Sources
- Russell SJ, et al. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022;387(13):1161-1172.
- Beta Bionics. iLet Bionic Pancreas clinical and product information.
- U.S. Food and Drug Administration. iLet Bionic Pancreas 510(k) clearance letter, 2023.
- American Diabetes Association. Standards of Care in Diabetes 2025 — Diabetes Technology.
